SEC Form 4 · accession 0001382963-15-000036
Viridian Therapeutics, Inc.\DE · VRDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Samuel D Riccitelli
Officer — President and CEO · Director
Period of report
Jun 19, 2015
Accepted (ET)
Jun 23, 2015 · 5:35 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590750
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 19, 2015 | M | 124,252 | — | A | 377,166 | D | |
| Common StockF2 | Jun 19, 2015 | F | 46,036 | $1.51 | D | 331,130 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F3 | — | Jun 19, 2015 | M | 124,252 | D | — | — | Common Stock | 124,252 | 248,503 | D |
Explanation of responses
- F1Restricted stock units converted into common stock on a one-for-one basis.
- F2Shares withheld to satisfy tax withholding obligations.
- F3On June 17, 2014, the reporting person was granted 745,511 restricted stock units. Under the terms of the restricted stock unit agreement, 372,756 shares were previously delivered. The remainder of this award will vest as follows: 16-2/3% of the award will vest on the one-year anniversary of the grant date; 16-2/3% of the award will vest on the eighteen-month anniversary of the grant date; and the remaining 16-2/3 of the award will vest on the two-year anniverary of the grant date. 124,252 of such shares vested on June 17, 2015 which represents 16-2/3% of the full award and are currently being issued.